| Contributors: |
Stoop, T. F.; Oba, A.; Wu, Y. H. A.; Beaty, L. E.; Colborn, K. L.; Janssen, B. V.; Al-Musawi, M. H.; Franco, S. R.; Sugawara, T.; Franklin, O.; Jain, A.; Saiura, A.; Sauvanet, A.; Coppola, A.; Javed, A. A.; Groot Koerkamp, B.; Miller, B. N.; Mack, C. E.; Hashimoto, D.; Caputo, D.; Kleive, D.; Sereni, E.; Belfiori, G.; Ichida, H.; Van Dam, J. L.; Dembinski, J.; Akahoshi, K.; Roberts, K. J.; Tanaka, K.; Labori, K. J.; Falconi, M.; House, M. G.; Sugimoto, M.; Tanabe, M.; Gotohda, N.; Krohn, P. S.; Burkhart, R. A.; Thakkar, R. G.; Pande, R.; Dokmak, S.; Hirano, S.; Burgdorf, S. K.; Crippa, S.; Van Roessel, S.; Satoi, S.; White, S. A.; Hackert, T.; Nguyen, T. K.; Yamamoto, T.; Nakamura, T.; Bachu, V.; Burns, W. R.; Inoue, Y.; Takahashi, Y.; Ushida, Y.; Aslami, Z. V.; Verbeke, C. S.; Fariña, A.; He, J.; Wilmink, J. W.; Messersmith, W.; Verheij, J.; Kaplan, J.; Schulick, R. D.; Besselink, M. G.; Del Chiaro, M. |
| Description: |
Importance: Preoperative chemo(radio)therapy is increasingly used in patients with localized pancreatic adenocarcinoma, leading to pathological complete response (pCR) in a small subset of patients. However, multicenter studies with in-depth data about pCR are lacking. Objective: To investigate the incidence, outcome, and risk factors of pCR after preoperative chemo(radio)therapy. Design, setting, and participants: This observational, international, multicenter cohort study assessed all consecutive patients with pathology-proven localized pancreatic adenocarcinoma who underwent resection after 2 or more cycles of chemotherapy (with or without radiotherapy) in 19 centers from 8 countries (January 1, 2010, to December 31, 2018). Data collection was performed from February 1, 2020, to April 30, 2022, and analyses from January 1, 2022, to December 31, 2023. Median follow-up was 19 months. Exposures: Preoperative chemotherapy (with or without radiotherapy) followed by resection. Main outcomes and measures: The incidence of pCR (defined as absence of vital tumor cells in the sampled pancreas specimen after resection), its association with OS from surgery, and factors associated with pCR. Factors associated with overall survival (OS) and pCR were investigated with Cox proportional hazards and logistic regression models, respectively. Results: Overall, 1758 patients (mean [SD] age, 64 [9] years; 879 [50.0%] male) were studied. The rate of pCR was 4.8% (n = 85), and pCR was associated with OS (hazard ratio, 0.46; 95% CI, 0.26-0.83). The 1-, 3-, and 5-year OS rates were 95%, 82%, and 63% in patients with pCR vs 80%, 46%, and 30% in patients without pCR, respectively (P < .001). Factors associated with pCR included preoperative multiagent chemotherapy other than (m)FOLFIRINOX ([modified] leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) (odds ratio [OR], 0.48; 95% CI, 0.26-0.87), preoperative conventional radiotherapy (OR, 2.03; 95% CI, 1.00-4.10), preoperative stereotactic body ... |